ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SLDB vs FDMT // EV/EBITDA & P/E VALUATION

Solid Biosciences Inc. (NASDAQ) VS. 4D Molecular Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: SLDB 0 — FDMT 5
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SLDB VS. FDMT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SLDB FDMT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -28.30% -6.70 FDMT /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -22.98% -15.53% -7.45 FDMT /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 180.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.17 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 5/9 -4.00 FDMT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 42.4 44.1 -1.79 FDMT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $685.2M $706.0M -$20.9M FDMT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SLDB REV FDMT REV SLDB GROSS % FDMT GROSS % SLDB FCF FDMT FCF
FY 2025 $0 $85.2M — — -$157.4M -$109.6M
FY 2024 $0 $37.0K — — -$100.7M -$138.4M
FY 2023 — $20.7M — — — -$75.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SLDB // BETA —
FDMT // BETA —